Get started

TEVA

THE WEEK AHEAD: TEVA, BIDU, RIG, XOPBIDU (44/42), RIG (33/56), and TEVA (49/53) announce earnings this week, with TEVA looking for a March to April volatility contraction of about 15%, BIDU, approximately 7.7%, and RIG, 6.9%. Instead of looking to play these pre-announcement for a volatility contraction (the contraction percentages aren't that compelling), I'll look to potentially short put/acquire/cover instead,* particularly since all of these underlyings have been hammered of late and are at the low end of their 52-week ranges. Pictured here is a Plain Jane, TEVA 20-ish delta 16 short put in the April expiry; it's paying .51 with a break even of 15.49. The more aggressive 30 would be at the 17 strike and is currently paying .79 with a 16.21 break even. On margin, the 16 short ties up about 320 to put on, the 17, 340, with respective returns on capital of 16% and 23% at max. The break evens represent a 15% discount over current price for the 16 short put; an 11% discount for the 17. The BIDU April 18th 155 (25 delta) is paying a 4.55 credit with a break even of 150.45, a potential 14.7% return on capital at max and a 11.4% discount over current price if assigned. As with TEVA, there is little point in holding shares if you don't have to, since it does not pay a divvy. If you end up in-the-money, roll as is and proceed to sell calls against to reduce cost basis. If you're not into tying up 31.00 in buying power on Baidu, there is RIG. Unfortunately, due to its size, you're going to have to go closer to the money to make it worthwhile in dollar and cents terms: the April 15th 8 short put (40 delta) is paying .57 with a break even of 7.43 -- a 35.6% potential return on capital at max and a 10.3% discount over current price if assigned. On the exchange-traded fund front, not much is hopping from a premium selling standpoint with VIX dropping into the 15's from its 2018 year-end highs of 36+, so I'll be looking to hand sit and keep powder dry for a higher volatility environment to get into nondirectional setups in broad market instruments. That being said, I will continue to sell premium in XOP, where the 30-day implied is over twice that of the broader market (34.1% versus SPY 15%). * -- The natural alternative should you not be interested in acquiring shares would be to roll the short put out in time "as is" if it hasn't worked out and then proceed to cover with a short call. The last two dividends were a paltry .07, so I could see not wanting to tie up buying power to be in the shares unless you absolutely have to.
NYSE:TEVA
by NaughtyPines
A Technical Analysis Look at TEVA Stock Any TEVA stock price falling on or below the hypothesized mean of $22.00, will signal the initiation of a buy order. On the other hand, any price rising above the hypothesized mean of $22.00 or within the range of $22.00 to $23.26 and above, will signal the initiation of a sell order. As of writing this Technical Indicator article, (November 5, 2018) the price of TEVA hit a low of $21.98, which is well within our target range of initiating a buy order. Therefore, if we had bought the stock at our hypothesized buy range of $22.00 or below, we would have made a nice profit of $0.85 (cents) per share because the stock closed at a $22.85 per share, a change of $0.26 (cents) per share, which is a 1.15% change for the day (November 5, 2018). Not only that, an early morning trade right after the market opened at 9:45 am would have given us a nice gain of $1.26 per share if we had followed our Mstardom Finance trading strategy of closing our long position or shorting the stock when it got to our range’s upper limit garget of $23.26. As soon as the price hit our $23.26 target, we would’ve had to exit the trade because in trading, greed causes traders to lose money, so as wise traders, we would’ve exited the trade several minutes before the stock got to its high point of $23.34. The Mstardom Finance community doesn’t care about a few extra pennies when we already got a sizable gain in our basket. The good thing is that this Mstardom Finance Trading Strategy is still relevant at the present time and in the not-so-distant future, once the hypothesized mean and the character of the TEVA stock stays the same. We are able to deduce such optimism because the stock has a very low volatility characteristic, based on our analytical assessment lend to us by our proprietary strategy. All we at Mstardom Finance cares about is helping the retail trader make money. So, when you hop over to Mstardom Finance, you will see articles, posts, and trading tools that provide the little retail trader with resources and information that will help him or her compete with the institutional or professional trader. This is what our upcoming trading book will be about, preventing the retail trader from being victims of the financial markets. Please click here to read the rest of the article, which includes a look at TEVA Fundamentals and how it has affected the movement of the stock Disclosure: (R) Mstardom Finance, Mstardom Finance does not provide investment advise.
NYSE:TEVA
by mstardom
TEVA is recharging the battery waiting next earnings release ($TEVA) was accelerating the uptrend but since some days it has come back on its path inside a bullish flag. It is important to note that next week earnings will be released so high volatility should be expected. Masch is about to turn on bullish mode RSI is quite down and vortex is neutral. I might expect that some investors will get long before the earnings pushing the price up but it is just an hypothesis. So far we are still inside the range with lower and upper edges showed on the chart.
NYSE:TEVA
by TRADOMICS_
TEVA up trend is acceleratingAs showed in the picture trend is accelerating as a sign of streght for TEVA. After some consolidation pauses we have a situation where RSI in pointing up, MACD non really clear as we have had a lateral movement, volatility stop positive. Red trendline is showing the acceleration. TP around 27 first and 30 dollars after. Despite some up and down of nasdaq, Teva has held the hit continuing the lateral movement rather than going down, another sign of strenght at the moment.
NYSE:TEVALong
by TRADOMICS_
$TEVA - Berkshire breakout? Disclaimer, TEVA is in a very bad financial position, with dwindling cashflows and large debt. Buffet has always been the king of "value investing", hence why a position in Teva isn't surprising from him - it's most likely that he sees the company as severely undervalued and is entering into stages of repair. Buffet's new position in Teva was widely publicised this week: fortune.com markets.businessinsider.com finance.yahoo.com Just after Buffet disclosed the position, Teva announced the U.S. release of the QVAR Redihaler Inhalation Aerosol. www.streetinsider.com -new form of asthma inhalation treatment -breath actuated I don't think this is too important. I'd much rather to follow his other position into AAPL rather than TEVA
NYSE:TEVA
by UnknownUnicorn2421992
1
Teva is now a buyAfter a couple of years where price has persistently followed the downtrend, last week Teva broke up such dynamic hreshold. Price has confirmed such trendline with a hammer 3 days ago at 17.04 dollars. Moreover we have the cross on the daily pattern between MA 50 and MA 200 turning to bullish set-up. Q1 earnings has been released beating expectations. SAR is positive and supertrend recently turned into bullish conformation as well. Trump is due to talk about drug prices this week but I don't deem Teva will be harshly impacted, because of the type of business. On a daily basis the hammer of three days ago confirmed by two green candles bear witness to a short term reversal. TP around 21.50/21.80
NYSE:TEVALong
by TRADOMICS_
TEVA Bullish bat pattern and demand zone before ERTEVA usually has HUGE move on its earning release day, which is 5/2. Here we got an bullish bat pattern but it's still way too far from the entry, while with regard to the potential huge move, it worth noticing beforehand and if it actually got crashed all the way there, it could be a high-risk high-reward trade! To start this trade ,there are 2 conditions to match 1. It gets slumped after ER 2. There are reversal signs between 11.50-12.00 Although it's still too early for this plan, but it doesn't hurt to make trading plans!! Let's see how it goes!
NYSE:TEVALong
by Trader_Joe_Lee
MNK, Another it's never too low to sell story?We've been through DDD,VRX,GPRO to the recent TEVA stories to me MNK is just another. Back to the days I was a proprietary trader, MNK is one of my favorite name as if I don't know what to trade in any given day I tried to short the name. Only if we kept "it's never too low to sell" in mind that we can catch this kind of profit, otherwise we might be stopped out each time when we want to buy the dip. I don't really suggest taking this inside week short as I know it takes gigantic risk appetite to take this trade, but I am more than willing to post in on TradingView to see how it goes afterwards.
M
by Trader_Joe_Lee
1
Teva strong resistence at 19.33, yet not a buyDespite the recent company's efforts to reduce its debit, from a technical point of view, I would be neutral with Teva until we will see a cross-over between slow 200d and fast 50d moving average on a daily chart pattern. For those who are aggressives MACD is still positive but keep in mind the resistence at 19.33 first and 20 after. Exhaustion gap betweeen 16 and 18 has been filled. Personally I see such movement as a prize for what the new CEO has done to reduce the impact of debit in short and mid term. Still 2018 will be critical to conferm that what has been undertaken is going toward in the right direction.
NYSE:TEVA
by TRADOMICS_
TEVA, inside day in front of exhaustion gap!TEVA was one of my favorite company to trade back to 2014-2015, and I was so bullish on the company then based on fundamental analysis~ After I stepped in the world of technical analysis and momentum trade, the story of TEVA has totally changed, too. There was a significant "island" formed by the exhaustion gap, and here comes an inside day. The short is the confirmation entry and the 8/21EMA correction combination; the long, on the other hand, is not a very great idea as it's fighting with the resistance. It's a better short than long inside day case, (compared to the relative idea below-- a both sided trade) Again, it doesn't imply I am predicting which direction it will break at all! Link to TradingView live chart! Welcome to click it as a like button lol~ tradingview.go2cloud.org
NYSE:TEVAShort
by Trader_Joe_Lee
2
THE WEEK AHEAD: SEAS, CTL, SQ, M EARNINGS; TEVA (NON)SEAS announces earnings on 11/7 before market open, with an implied volatility of 71%, which is at the upper end of its range over the previous 52 week period. The November 17th 11 short straddle is paying 1.37 at the mid with a comparable iron fly probably not paying enough to make it worthwhile (less than 1/4 the width of the longs). CTL (implied volatility of 62%; at the top of its 52 week range) announces on 11/8 after market close. The quasi-short straddle or tight short strangle 16/17 in the November 17th expiry pays 1.27 with break evens slightly wide of expected move. As with SEAS, the iron fly doesn't pay enough to be worthwhile ... . SQ also announces on 11/8 after market close. With an implied volatility of 55, it's in the top quarter of its annual range. The November 17th 33/42 short strangle camped out at around the 20 delta strikes yields 1.03 in credit, implying that a defined risk play like an iron condor won't pay one-third the width of the wings, although it may be worth pricing it out closer to earnings. M announces on 11/9 before market open (implied volatility 55, top quarter of range). The November 17th 18/19 tight short strangle/near short straddle pays 1.43 at the mid, with break evens wide of the expected. The November 17th 14/18/19/23 comparable defined risk iron condor/fly play pays 1.86, which is close to 1/4 of the width of the longs, so worth a check shortly before the announcement. TEVA's earnings are in the rear view mirror, but its implied volatility remains elevated here at 65 -- at the upper end of its 52 week range. The December 15th 30 delta strike at 10 pays .30 as a potential short put/acquire/cover play with a cost basis of 9.70 in any acquired shares. For the patient and/or fearful of the possibility that this company's another VRX, going monied covered call out of the box with a share purchase here at 11.40 and a sale of the March 16th 10 call would cost 9.06 to put with a max profit of .94.
C
by NaughtyPines
THE WEEK AHEAD: COST, BBRY, TEVA, MATEarnings COST announces earnings on Thursday after market close. With a background implied volatility of 21%, it doesn't meet my basic earnings play sniff test, but naturally that can increase running into earnings, so it may be worth keeping an eye on. Preliminarily, the Oct 20th 158/170 short strangle currently pays 2.21 at the mid with break evens around the 1 standard deviation line for both sides. The defined risk version of that play, a 155/158/170/173 iron condor, brings in 1.00, with break evens wide of the expected on both sides. (I looked at using the Oct 13th expiry to take maximum advantage of any vol contraction post-earnings, but strikes where I would want to set up my tent were less than ideal). Non-Earnings Post-earnings, BBRY implied volatility remains fairly high at 46.25%, placing it in the upper one quarter of the where it's been over the past 52 weeks. Given the size of the underlying, the only play that makes sense from a nondirectional standpoint is a Nov 17th 11 short straddle, which is paying 1.24 at the mid with break evens at 9.75 and 12.25. The generic drug maker TEVA's implied is at 51.31%, which is around the middle of its range over the past 52. It's not quite where I'd like to see it, and the Nov 17th 15/20 short strangle is only paying .80 at the mid with break evens short of the 1 standard deviation line In contrast, the Nov 17th 17.5 short straddle is paying 2.46 with break evens wide of the expected on both sides, but the comparable iron fly -- a Nov 17th 12.5/17.5/17.5/22.5 only pays 2.20, short of the one-quarter of the width of the longs I like to get out of those. For those looking to strategically acquire shares or to just sell directional premium, the 30 delta Nov 10th 16 short put is paying .52 at the mid with a break even of 15.48. Toy maker MAT has the right rank/implied metrics here, but with earnings a mere 17 days out, the preference is wait to put on a play shortly before earnings to take maximum advantage of vol contraction. Exchange-Traded Funds These are my bread and butter trades, but there's little bread and no butter here. The highest implied volatility exchange traded fund is EWZ at 31.43%, but it's in the lower one-fourth of where it's been over the past year. GDXJ follows with 29.93%; XOP, 25.96%; GDX, 23.25%; and OIH, 24.21%, all at the bottom end of their ranges and, in any event, below 35% implied generally. VIX et al. VIX finished Friday at sub-10 levels and its "little buddies" (VXX, UVXY, SVXY) continue to be cannibalized by contango. Sit on your hands for any VIX "Term Structure" trade (the first /VX future trading at >16 is in April) and wait for a VXST/VIX ratio pop to greater than 1.15 (Friday finish: 83.6) to put on plays in VXX, UVXY, and/or SVXY.
NASDAQ:COST
by NaughtyPines
Portfolio Position: Teva Pharmaceuticals $TEVATeva Pharmaceuticals $TEVA has shed over 50% of its value following its $6.1B impairment charge and 75% dividend slash in its latest quarterly report. Pros: - The company continues to expect double digit sales growth from its recent Actavis acquisition from Allergan $AGN. - Teva expects over 1,500 new drugs to launch in 2017, with over 900 drugs still pending approvals. - The company is divesting its non-core organic revenue drivers, expected to bring in over $5B in 2017 and boost margins. - Aggressive cost cutting, saving over $1.6B annually is expected to boost Net Income and Margins. Risks: - Teva's blockbuster drug Copaxone is under competitive pressure, losing market share in 2017 & is expected to continue in 2018. - Sentiment: The company still trades in a highly retail environment being effected by mass hysteria, boding bad for share price. Targets: I initiate TEVA with a $30 PT for the next 12 months, throughout 2018. For the full review: seekingalpha.com
NYSE:TEVALong
by TraderDanER
TEVA, A potential both-sided inside day.It's really tough for TEVA investors since 2016, everything seems so bad for this generic drugs giant. They finally got a new CEO and got good news from FDA, which enabled the stock price to bounce 20% in 2 days. Here we got this inside day after such a big movement, so the direction it broke becomes so important to the following sentiment on this name. Trading this inside day directly is also an OK idea, but I would more like to find intraday trade in 5/15/30 minute chart as I don't really want to swing this name unless I have a very successful day-trade. *For educational use only
NYSE:TEVA
by Trader_Joe_Lee